554 related articles for article (PubMed ID: 10926802)
1. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
Gründker C; Völker P; Schulz KD; Emons G
Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
Gründker C; Völker P; Emons G
Endocrinology; 2001 Jun; 142(6):2369-80. PubMed ID: 11356684
[TBL] [Abstract][Full Text] [Related]
3. Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells.
Günthert AR; Gründker C; Böttcher B; Emons G
Anticancer Res; 2004; 24(3a):1727-32. PubMed ID: 15274347
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
Chatzistamou I; Schally AV; Sun B; Armatis P; Szepeshazi K
Br J Cancer; 2000 Oct; 83(7):906-13. PubMed ID: 10970693
[TBL] [Abstract][Full Text] [Related]
5. GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells.
Eicke N; Günthert AR; Emons G; Gründker C
Int J Oncol; 2006 Nov; 29(5):1223-9. PubMed ID: 17016655
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase C-independent stimulation of activator protein-1 and c-Jun N-terminal kinase activity in human endometrial cancer cells by the LHRH agonist triptorelin.
Gründker C; Schlotawa L; Viereck V; Emons G
Eur J Endocrinol; 2001 Nov; 145(5):651-8. PubMed ID: 11720885
[TBL] [Abstract][Full Text] [Related]
7. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.
Emons G; Schröder B; Ortmann O; Westphalen S; Schulz KD; Schally AV
J Clin Endocrinol Metab; 1993 Dec; 77(6):1458-64. PubMed ID: 8263128
[TBL] [Abstract][Full Text] [Related]
8. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.
Gründker C; Emons G
Reprod Biol Endocrinol; 2003 Oct; 1():65. PubMed ID: 14594454
[TBL] [Abstract][Full Text] [Related]
9. Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats.
Horvath JE; Bajo AM; Schally AV; Kovacs M; Herbert F; Groot K
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):15048-53. PubMed ID: 12409615
[TBL] [Abstract][Full Text] [Related]
10. Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats.
Kovacs M; Schally AV
Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12197-202. PubMed ID: 11593037
[TBL] [Abstract][Full Text] [Related]
11. Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells.
Günthert AR; Gründker C; Hollmann K; Emons G
Biochem Biophys Res Commun; 2002 May; 294(1):11-5. PubMed ID: 12054733
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells.
Gründker C; Günthert AR; Hellriegel M; Emons G
Eur J Endocrinol; 2004 Nov; 151(5):619-28. PubMed ID: 15538941
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor.
Gründker C; Schlotawa L; Viereck V; Eicke N; Horst A; Kairies B; Emons G
Eur J Endocrinol; 2004 Jul; 151(1):141-9. PubMed ID: 15248835
[TBL] [Abstract][Full Text] [Related]
14. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines.
Emons G; Ortmann O; Becker M; Irmer G; Springer B; Laun R; Hölzel F; Schulz KD; Schally AV
Cancer Res; 1993 Nov; 53(22):5439-46. PubMed ID: 8221683
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone-releasing hormone agonist triptorelin antagonizes signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines.
Emons G; Muller V; Ortmann O; Grossmann G; Trautner U; Stuckrad B; Schulz K; Schally A
Int J Oncol; 1996 Dec; 9(6):1129-37. PubMed ID: 21541621
[TBL] [Abstract][Full Text] [Related]
16. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
Günthert AR; Gründker C; Bongertz T; Schlott T; Nagy A; Schally AV; Emons G
Am J Obstet Gynecol; 2004 Oct; 191(4):1164-72. PubMed ID: 15507937
[TBL] [Abstract][Full Text] [Related]
17. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145.
Moretti RM; Marelli MM; Dondi D; Poletti A; Martini L; Motta M; Limonta P
J Clin Endocrinol Metab; 1996 Nov; 81(11):3930-7. PubMed ID: 8923840
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix.
Siejka A; Schally AV; Block NL; Barabutis N
BJU Int; 2010 Nov; 106(9):1382-8. PubMed ID: 20151966
[TBL] [Abstract][Full Text] [Related]
19. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma.
Irmer G; Bürger C; Müller R; Ortmann O; Peter U; Kakar SS; Neill JD; Schulz KD; Emons G
Cancer Res; 1995 Feb; 55(4):817-22. PubMed ID: 7850795
[TBL] [Abstract][Full Text] [Related]
20. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
Lamharzi N; Halmos G; Jungwirth A; Schally AV
Int J Oncol; 1998 Sep; 13(3):429-35. PubMed ID: 9683774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
